insulin glargine

FDA Drug Profile — Lantus, Insulin glargine U-300, LANTUS SOLOSTAR, Lantus Solostar, TOUJEO Max

insulin glargine is listed in the FDA National Drug Code directory with 17 NDC codes, marketed under brand names including Lantus, Insulin glargine U-300, LANTUS SOLOSTAR. Available dosage forms: injection, solution, powder.

Drug details

Generic Name
insulin glargine
Brand Names
Lantus, Insulin glargine U-300, LANTUS SOLOSTAR, Lantus Solostar, TOUJEO Max, TOUJEO, Insulin Glargine Solostar, Insulin glargine U-300 Max
Application Number
BLA021081
Sponsor
A-S Medication Solutions
NDC Codes
17
Dosage Forms
INJECTION, SOLUTION, POWDER
Routes
SUBCUTANEOUS
Active Ingredients
INSULIN GLARGINE

Indications and Usage

1 INDICATIONS AND USAGE BASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for treating diabetic ketoacidosis. ( 1 ) Limitations of Use BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.